CMSC: Domestic policies will be significantly strengthened by 2025, with the brain-computer interface industry reaching a critical point of explosion.

CMSC released a research report stating that the downstream application scenarios of brain-computer interface technology are rich, with the medical field being the main battlefield and tremendous potential in non-medical markets. Currently, the industry is at a crucial turning point, driven by policy and demand, transitioning from a long-term academic exploration stage to accelerated commercial applications. By 2025, domestic policies will significantly increase: included in the "Six Major Future Industries" of the "13th Five-Year Plan," receiving systematic support from top-level design to local policies to fully promote industry development. CMSC's main points are as follows: What is a brain-computer interface? What are the applicable scenarios? A brain-computer interface is a technology that establishes direct communication between the brain and external devices, enabling bidirectional interaction from neural signals to control commands. Its technical paths are mainly categorized into invasive, semi-invasive, and non-invasive types. The report believes that the three types of technical paths have no absolute advantages or disadvantages, with applicability depending on specific scenarios. The medical field focuses more on precision and stability, while consumer applications prioritize effectiveness, safety, and convenience. The current technology is evolving from a unidirectional "read" to a closed-loop system of "perceive-control-feedback," continuously pushing boundaries. The downstream application scenarios are rich, with the medical field as the main battlefield and tremendous potential in non-medical markets. Medical applications account for 56%, while non-medical fields such as consumer, industrial, and education combined account for 44%, demonstrating strong expansion potential. According to Forward Industry Research Institute, the global BCI market size is expected to increase from $1.98 billion in 2023 to $7.63 billion in 2029; the Chinese market size is rapidly growing, reaching $1.73 billion in 2023 with a global share increase to 12.5%. Under the drive of policies, demand, and innovation systems, the future space is broad. What are the challenges in the development of the brain-computer interface industry? The BCI industry is in a key period of rapid development, facing multiple unresolved issues. Technically, balancing high-throughput, high signal-to-noise ratio signal acquisition with long-term biocompatibility is a core challenge, while the generalization ability of decoding algorithms and the precision of adaptive control still need breakthroughs. Clinically, the long-term safety and efficacy of invasive products need verification through large-scale trials, and the delineation of indications, standardization of surgeries, and postoperative management systems are not yet mature. In terms of industrialization, upstream core components (such as high-performance electrodes and dedicated chips) still rely on interdisciplinary collaboration, midstream software-hardware integration and ecosystem construction are still in the early stages, downstream medical payment paths are unclear, consumer-level product user experience and real demand matching are insufficient, and global regulations and ethical frameworks are still being explored, collectively hindering the industry's scaled landing. Global and Chinese progress in brain-computer interface? Guided by policies and market demand, the global BCI industry ecosystem is accelerating development. Leading global companies like Neuralink and Synchron are pushing brain signal acquisition and interaction systems towards higher precision and lower trauma through innovative pathways like high-throughput flexible implantation and vascular intervention. The Chinese brain-computer interface industry has made significant progress in system integration and application landing, forming a diversified enterprise matrix represented by Strong Brain Technology (non-invasive), Borui Kang (semi-invasive), Xinwei Medical (invasive), etc. By 2025, domestic policies will significantly increase: included in the "Six Major Future Industries" of the "13th Five-Year Plan," receiving systematic support from top-level design to local policies to fully promote industry development. Related targets Primary market: Strong Brain Technology, Borui Kang, Jielitai Medical, Xindra Medical, Zhiran Medical, Jingyu Medical, Pinchi Medical, etc.; Secondary market: Upstream (Medprin Regenerative Medical Technologies, MeHow Innovative); Midstream (HEARTCARE-B, Xiangyu Medical, Jiangsu Apon Medical Technology, Nanjing Medlander Medical Technology, Nanjing Vishee Medical Technology Co., Ltd., Beijing Chieftain Control Technology Group, BMC Medical, Lepu Medical Technology, Innovative Medical Management, Hangzhou Biotest Biotech, Cofoe Medical Technology); Downstream (Sanbo Hospital Management); Others (Guangdong Dowstone Technology, Hangzhou Radical Energy-Saving Technology, Shenzhen Leaguer, Yijiahe Technology), etc. Risk warnings: Risks of new product R&D failure or registration delays, risks of increasing market competition intensity, policy risks.